Award
National Cancer Institute 4R01CA294793-03
Elucidating resistance mechanisms and enhancing response to immune checkpoint blockade in central nervous system metastases from breast cancer
Recipient
Massachusetts General Hospital
Award Amount
$2,082,604.00
Ceiling
$2,082,604.00
Awarded
June 25, 2026
Identifier
4R01CA294793-03
NIH grant awarded to Massachusetts General Hospital to study resistance mechanisms and improve immunotherapy response in CNS metastases from breast cancer, with a $2,082,604 award amount for research spanning 2024 to 2029.
Description
This project focuses on understanding and overcoming resistance to immunotherapy in CNS metastases of breast cancer, with a translational approach involving genomic profiling, immune phenotyping, and preclinical models. The study aims to identify biomarkers of response and resistance to immunotherapy and potentially new therapeutic targets for patients with brain metastases from breast cancer. It involves conducting Phase II trials, profiling DNA and RNA from cancer tissues, blood, and cerebrospinal fluid, and using cutting-edge single-cell technologies to understand resistance mechanisms. Mouse models will be used to test combination therapies, including CDK inhibition with immune checkpoint blockade, to uncover mechanisms of treatment failure and develop improved therapeutic strategies.